Drug Profile
Research programme: cancer therapeutics - HUTCHMED
Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Hutchison MediPharma
- Class Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists; Fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 09 Jun 2021 Hutchison MediPharma has been acquired and merged into HUTCHMED
- 28 Oct 2019 No recent reports of development identified for preclinical development in Solid-tumours in World (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in China (PO)